Mentari Therapeutics stock kpis
Want to see MTRI full AI Analyst Report?
Revenue By Segment
Shows how much revenue each business segment generates, highlighting the company's strengths and potential areas for growth or concern based on segment performance.
BayMedica, a segment of InMed Pharmaceuticals, has shown a volatile revenue trajectory with significant growth spikes, notably in mid-2023, followed by fluctuations. Despite a peak in Q2 2023, recent quarters indicate a stabilization trend, suggesting efforts to maintain consistent revenue streams. The InMed segment, however, has consistently reported zero revenue, highlighting a potential strategic focus on BayMedica's performance. Investors should watch for strategic updates or market developments that could impact BayMedica's revenue stability and InMed's future contributions.
MTRI Revenue By Segment
| Date | InMed | BayMedica |
|---|---|---|
| Jun 30, 2026 | C$0.00 | C$576.34K |
| Mar 31, 2026 | C$0.00 | C$659.85K |
| Dec 31, 2025 | C$0.00 | C$820.19K |
| Sep 30, 2025 | C$0.00 | C$1.12M |
| Jun 30, 2025 | C$0.00 | C$1.30M |
| Mar 31, 2025 | C$0.00 | C$1.26M |
| Dec 31, 2024 | C$0.00 | C$1.11M |
| Sep 30, 2024 | C$0.00 | C$1.26M |
| Jun 30, 2024 | C$0.00 | C$1.28M |
| Mar 31, 2024 | C$0.00 | C$1.17M |
| Dec 31, 2023 | C$0.00 | C$1.24M |
| Sep 30, 2023 | C$0.00 | C$901.86K |
| Jun 30, 2023 | C$0.00 | C$2.31M |
| Mar 31, 2023 | C$0.00 | C$1.03M |
| Dec 31, 2022 | C$0.00 | C$469.78K |
| Sep 30, 2022 | C$0.00 | C$320.79K |
| Jun 30, 2022 | C$0.00 | C$514.76K |
| Mar 31, 2022 | C$0.00 | C$309.58K |
| Dec 31, 2021 | C$0.00 | C$265.09K |
| Sep 30, 2021 | C$0.00 | C$0.00 |
